Travere Therapeutics to Present at Upcoming Investor Conferences
Travere Therapeutics (NASDAQ: TVTX) will participate in two upcoming conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Travere Therapeutics (NASDAQ: TVTX) will participate in two upcoming conferences. The first is the Guggenheim Healthcare Talks scheduled for April 4, 2023, at 3:55 p.m. ET. The second is the BofA Securities 2023 Health Care Conference on May 10, 2023, at 3:40 p.m. PT. Live webcasts of both presentations will be available on the company's Investor page, and replays will be accessible for up to 30 days post-event. Travere is dedicated to developing therapies for rare diseases, working closely with patients and the healthcare community to address urgent treatment needs.
Details
News Market Reaction – TVTX
The recorded move for TVTX in the trading session of this news was +5.68%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, March 28, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences:
Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days
Tuesday, April 4, 2023, at 3:55 p.m. ET
BofA Securities 2023 Health Care Conference
Wednesday, May 10, 2023, at 3:40 p.m. PT
Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-presentations. Replays will be available for up to 30 days following each event.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.
| Media: Nivi Nehra Vice President, Corporate Communications 888-969-7879 mediarelations@travere.com | Investors: Naomi Eichenbaum Vice President, Investor Relations 888-969-7879 IR@travere.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.